

## FORM 51-102F3

### Material Change Report

**Item 1. Name and Address of Company**

Blackhawk Growth Corp. (the “Company”)  
Suite 2200, 885 West Georgia Street  
Vancouver, B.C., V6C 3E8

**Item 2. Date of Material Change**

News Release dated December 16, 2020.

**Item 3. News Release**

The Company disseminated a news release concerning the material change described herein on December 16, 2020 and subsequently filed a copy on SEDAR at [www.sedar.com](http://www.sedar.com).

**Item 4. Summary of Material Change**

Blackhawk’s psychedelic development and wellness treatment center set to open first Canadian location.

**Item 5. Full Description of Material Change**

Vancouver, British Columbia – TheNewswire – December 16, 2020 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (US OTC:BLRZF) (the “Company”), is pleased to announce that one of its portfolio companies, Trip Pharma Inc. (“Trip Pharma”), a mental health and wellness company focused on the production of psychedelics and psychedelic-enhanced psychotherapy, will be opening its first medical center in Edmonton, Alberta specializing in the administration of holistic and psychedelic-enhanced psychotherapy.

The center will be branded *LeichtMind* (pronounced “light mind”) and is scheduled to open its doors in early Q1 2021. The goal of this center is to provide a much-needed safe community and space for patients seeking out specific revolutionary treatments, allowing them to access Trip Pharma’s proprietary produced medications and compounds.

Led by Dr. Krista Leicht, this purpose-built psychiatric clinic will provide patients with best-in-class care and complementary treatments while providing a welcoming and stigma-free environment. Dr. Leicht will be joined by a team of like-minded Psychiatrists, Psychologists and Medical Practitioners whose aim is to combat the mental health crisis facing Canada and using telemedicine to potentially reach anyone in the world.

“Leading research institutions like Johns Hopkins University and New York University have presented the positive effects of psychedelic-enhanced psychotherapy” said Frederick Pels, CEO of Blackhawk Growth Corp. “It is truly amazing to be involved with

such a forward-thinking team that we have assembled in Trip Pharma and LeichtMind. As LeichtMind becomes a leader and facilitator of the profound, sustainable results that these treatments can provide, growth is inevitable. I look forward to updating our shareholders on these initiatives in the near future.”

As part of our goal to expand the possible treatment options in the clinic, Trip Pharma has begun the process of completing an application for a controlled drugs and substances dealers licence in Canada. The company is working to source a library of psilocybin cubensis genetics that will provide a supply of high-quality products for use in research and prescription for clinical patients.

Once the clinic is fully operational, it is the Company’s intention to have Blackhawk’s 100% owned telemedicine platform – “*Talk to Doc*” be the exclusive provider for patients to connect to medical professionals virtually at LeichtMind.

#### About Dr. Krista Leicht

Dr. Leicht is a Canadian-trained and Alberta-licensed medical doctor and psychiatrist, who brings over 20 years of clinical experience to the team. She has divided her time in a busy practice between inpatient and outpatient care, treating both the general adult psychiatry population and specializing in addressing the complex needs of developmentally handicapped individuals. Dr. Leicht maintains a hospital practice at Alberta Hospital Edmonton and sees outpatients in a South Edmonton clinic. She continues to teach medical students, residents and provides further education to family-practice colleagues. Dr. Leicht’s goal in clinical practice and in her own life has always been to go beyond — to provide unique and innovative treatments that better enrich the lives of patients is her mission.

For further information please contact:

**Frederick Pels, Chief Executive Officer**

**(403)-991-7737**

**[fred@blackhawkgrowth.com](mailto:fred@blackhawkgrowth.com)**

**.Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable

**Item 7. Omitted Information**

Not applicable

**Item 8. Executive Officer**

The following senior officer of the Company is knowledgeable about the material change disclosed in this report.

Frederick Pels  
Chief Executive Officer  
Telephone: 403-991-7737

**Item 9.**

**Date of Report**

December 16, 2020